Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
暂无分享,去创建一个
H. Moch | R. Dummer | P. Schraml | O. Michielin | D. Mihic-Probst | A. Ochsenbein | R. V. Von Moos | M. Simcock | A. von Teichman | B. Seifert | M. Schläppi | R. von Moos | Marc Schläppi